tbuckley/cabot-search huggingface dataset:
The sodium-bicarbonate cotransporter Slc4a5 mediates feedback at the first synapse of vision
Authors: Rei Morikawa, Tiago M Rodrigues, Helene Marianne Schreyer, Cameron S Cowan, Sarah Nadeau, Alexandra Graff-Meyer, Claudia P Patino-Alvarez, Mohammad Hossein Khani, Josephine Jüttner, Botond Roska
Journal: Neuron (2024)
Disparities in the Utilization of MRI for Prostate Cancer Detection: A Population-Based Study
Authors: Christiane J El Khoury, Stephen J Freedland, Krupa Gandhi, Scott W Keith, Nikita Nikita, Amy Shaver, Swapnil Sharma, Wm Kevin Kelly, Grace Lu-Yao
Journal: JNCI Journal of the National Cancer Institute (2024)

Racial disparities exist in prostate cancer (PCa) care and outcomes. Ultrasound-guided biopsy may miss a significant portion of clinically significant PCa while magnetic resonance imaging (MRI) improves its detection. This study aims to investigate demographic and SES factors influencing MRI utilization for PCa detection.
Pig-to-human kidney xenotransplants using genetically modified minipigs
Authors: Yi Wang, Gang Chen, Dengke Pan, Hui Guo, Hongtao Jiang, Jianli Wang, Hao Feng, Songzhe He, Jiaxiang Du, Man Zhang, Tao Li, Yong Wang, Hang Yu, Huiling Gan, Quan Wen, Zhian Song, Desheng Li, Yifan Yu, Huanliang Wang, Bing Li, Yong You, Shen Zhou, Mingfa Wang, Lili Liu, Liang Xu, Meng Yang, Hua Pei, Kang Zhang, Zhonghua K Chen
Journal: Cell Reports Medicine (2024)
Virus Infection Induces Immune Gene Activation with CTCF Anchored Enhancers and Chromatin Interactions in Pig Genome
Authors: Jianhua Cao, Ruimin Ren, Xiaolong Li, Xiaoqian Zhang, Yan Sun, Xiaohuan Tian, Ru Liu, Xiangdong Liu, Yijun Ruan, Guoliang Li, Shuhong Zhao
Journal: Genomics Proteomics & Bioinformatics (2024)
Immunomodulatory Therapy for Ischemic Heart Disease
Authors: Xinye Zhao, Thomas Williamson, Yanqing Gong, Jonathan A. Epstein, Yi Fan
Journal: Circulation (2024)

Ischemic heart disease is a leading cause of death worldwide, manifested clinically as myocardial infarction (and ischemic cardiomyopathy. Presently, there exists a notable scarcity of efficient interventions to restore cardiac function after myocardial infarction. Cumulative evidence suggests that impaired tissue immunity within the ischemic microenvironment aggravates cardiac dysfunction, contributing to progressive heart failure. Recent research breakthroughs propose immunotherapy as a potential approach by leveraging immune and stroma cells to recalibrate the immune microenvironment, holding significant promise for the treatment of ischemic heart disease. In this Primer, we highlight three emerging strategies for immunomodulatory therapy in managing ischemic cardiomyopathy: targeting vascular endothelial cells to rewire tissue immunity, reprogramming myeloid cells to bolster their reparative function, and utilizing adoptive T cell therapy to ameliorate fibrosis. We anticipate that immunomodulatory therapy will offer exciting opportunities for ischemic heart disease treatment.
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial
Authors: Dana E Rathkopf, Guilhem Roubaud, Kim N Chi, Eleni Efstathiou, Gerhardt Attard, David Olmos, Eric J Small, Marniza Saad, Elena Castro, Won Kim, Daphne Wu, Kristi Bertzos, Shiva Dibaj, Jenny Zhang, Peter Francis, Matthew R Smith
Journal: European Urology (2024)
The Role of Multiparametric Magnetic Resonance Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in the Management of Patients with Bladder Cancer: Vision of the American College of Radiology VI-RADS Steering Committee
Authors: Valeria Panebianco, Alberto Briganti, Jason Efstathiou, Samuel Galgano, Lyndon Luk, Valdair Francisco Muglia, Bernadette Redd, Maarten de Rooij, Mitsuru Takeuchi, Sungmin Woo, J Alfred Witjes, Hebert Alberto Vargas
Journal: European Urology (2024)
Response by Giacoppo et al to Letter Regarding Article “Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis”
Authors: Daniele Giacoppo, Claudio Laudani, Giovanni Occhipinti, Marco Spagnolo, Antonio Greco, Carla Rochira, Federica Agnello, Davide Landolina, Maria Sara Mauro, Simone Finocchiaro, Placido Maria Mazzone, Nicola Ammirabile, Antonino Imbesi, Carmelo Raffo, Sergio Buccheri, Davide Capodanno
Journal: Circulation (2024)
Targeting SHCBP1 Inhibits Tumor Progression by Restoring Ciliogenesis in Ductal Carcinoma
Authors: Wengui Shi, Lianshun Li, Huiming Zhao, Zhengyang Li, Zhijian Ma, Qianlin Gu, Huili Ye, Xiangyan Jiang, Yuman Dong, Long Qin, Huinian Zhou, Zeyuan Yu, Zuoyi Jiao
Journal: Cancer Research (2024)

Primary cilia detect and transmit environmental signals into cells. Primary cilia are absent in a subset of ductal carcinomas characterized by distinctive biological activities, and recovery of cilia with normal functionality has been shown to have therapeutic potential in some cancer types. Therefore, elucidation of the underlying mechanism and clinical significance of ciliary loss in ductal carcinomas could help develop effective treatment strategies. Here, we identified a link between SHCBP1 and cilia in ductal carcinomas. Shcbp1 knockout in transgenic mice profoundly impeded tumor progression and metastasis, prolonging survival. Single-cell transcriptome analysis revealed a functional connection between SHCBP1 deficiency and increased tumor ciliogenesis. SHCBP1 ablation restored ciliogenesis in unciliated ductal carcinoma by promoting the proximity between the midbody remnant (MBR) and centrosome through enhanced Rab8 GTPase activity and Rab8GTP positioning within the MBR. Inhibition of tumor progression by SHCBP1 loss relied on the recovery of ciliogenesis. Analysis of a large cohort of patients with ductal carcinoma revealed a negative correlation between SHCBP1-induced ciliary loss and patient prognosis. Restoring ciliogenesis via SHCBP1 ablation elicited therapeutic effects in patient-derived xenograft models. Together, this study delineates that induction of MBR-centrosome proximity through SHCBP1-deficiency reactivates ciliogenesis, offering unique opportunities for the treatment of unciliated ductal carcinomas.
Single-cell map of diverse immune phenotypes in the metastatic brain tumor microenvironment of non-small-cell lung cancer
Authors: Liang Wang, Min Chao, Run-Run Han, Lei Li, Lei Dong, Fan Chen, Ming-Zhu Jin, Li Gao, Yuan Wang, Da-Yun Feng, Gang Zhu, Wei Guo, Wen-Jian Zhao, Shi-Jia Jin, Dong-Ping Wei, Wei Sun, Jin-Xiang Dai, Wei-Lin Jin
Journal: International Journal of Surgery (2024)
Clinical outcomes of preservation versus resection of portal/superior mesenteric vein during pancreaticoduodenectomy in pancreatic cancer patients who respond to neoadjuvant treatment: A retrospective cohort study
Authors: Yoon Soo Chae, Hye-Sol Jung, Won-Gun Yun, Youngmin Han, Young Jae Cho, Mirang Lee, Wooil Kwon, Joon Seong Park, Jin-Young Jang
Journal: International Journal of Surgery (2024)

Background: R0 rates have increased as neoadjuvant treatment (NAT) has become the primary treatment for pancreatic ductal adenocarcinoma (PDAC) with venous involvement, suggesting a decrease in venous tumor infiltration. The aim of this study was to investigate the clinical outcomes of preserving the portal/superior mesenteric vein (PV/SMV) during pancreaticoduodenectomy (PD) in PDAC patients who underwent NAT. Material and Methods: The 113 patients with resectable and borderline resectable PDAC with venous involvement who responded to NAT and underwent curative PD between 2012 and 2022 were retrospectively reviewed. Results: Among the 113 patients, PV/SMV preservation (PVP) was performed in 68 patients (60.2%), and PV/SMV resection (PVR) was performed in 45 patients (39.8%). There was no significant difference in the R0 rate, 5-year overall survival (OS) and recurrence-free survival between the two groups. PV/SMV stenosis within 3 months after surgery was more common in the PVR group than in the PVP group (1.5% versus 22.2%; P &lt; 0.001), and 5-year PV/SMV stenosis-free survival was significantly higher in the PVP group than in the PVR group (76.5% versus 53.4%; P =0.014). Multivariate analysis showed that gemcitabine-based neoadjuvant chemotherapy was associated with poor OS. PVR, clinically relevant postoperative pancreatic fistula, and locoregional recurrence were independent risk factors for PV/SMV stenosis. Conclusion: The PVP group had similar oncologic outcomes and better vessel-functional outcomes than the PVR group. Therefore, if dissection is possible and there is a high likelihood of achieving R0 resection after NAT, routine PVR may be unnecessary in PDAC patients with venous involvement.
Advances in mechanism and management of bone homeostasis in osteonecrosis: a review article from basic to clinical applications
Authors: Xiao-Na Xiang, Hong-Chen He, Cheng-Qi He
Journal: International Journal of Surgery (2024)

Osteonecrosis, characterized by bone cell death leading to impaired bone recovery, causes challenges in bone homeostasis maintenance. Bone homeostasis relies on the delicate balance between osteoclasts and osteoblasts, encompassing a series of complex and strictly regulated biological functions. Current treatments, including conservative therapies and surgeries, often fall short of expected outcomes, necessitating a reorientation towards more effective therapeutic strategies according to the pathogenesis. In this review, we hierarchically outlined risk factors, emerging mechanisms, and last-decade treatment approaches in osteonecrosis. By connecting mechanisms of bone homeostasis, we proposed future research directions should be focused on elucidating risk factors and key molecules, performing high-quality clinical trial, updating practice, and accelerating translational potential.
Single-cell Transcriptomic Analysis Identifies Senescent Osteocytes that Trigger Bone Destruction in Breast Cancer Metastasis
Authors: Japneet Kaur, Manish Adhikari, Hayley M. Sabol, Aric Anloague, Sharmin Khan, Noriyoshi Kurihara, Marta Diaz-delCastillo, Christina Møller Andreasen, Charles Lowry Barnes, Jeffrey B. Stambough, Michela Palmieri, Olivia Reyes-Castro, Jennifer Zarrer, Hanna Taipaleenmäki, Elena Ambrogini, Maria Almeida, Charles A. O’Brien, Intawat Nookaw, Jesus Delgado-Calle
Journal: Cancer Research (2024)

Breast cancer bone metastases increase fracture risk and are a major cause of morbidity and mortality among women. Upon colonization by tumor cells, the bone microenvironment undergoes profound reprogramming to support cancer progression, which disrupts the balance between osteoclasts and osteoblasts and leads to bone lesions. A deeper understanding of the processes mediating this reprogramming could help develop interventions for treating patients with bone metastases. Here, we demonstrated that osteocytes (Ot) in established breast cancer bone metastasis develop premature senescence and a distinctive senescence-associated secretory phenotype (SASP) that favors bone destruction. Single-cell RNA sequencing identified Ots from mice with breast cancer bone metastasis enriched in senescence, SASP markers, and pro-osteoclastogenic genes. Multiplex in situ hybridization and artificial intelligence-assisted analysis depicted Ots with senescence-associated satellite distension, telomere dysfunction, and p16Ink4a expression in mice and patients with breast cancer bone metastasis. Breast cancer cells promoted Ot senescence and enhanced their osteoclastogenic potential in in vitro and ex vivo organ cultures. Clearance of senescent cells with senolytics suppressed bone resorption and preserved bone mass in mice with breast cancer bone metastasis. These results demonstrate that Ots undergo pathological reprogramming by breast cancer cells and identify Ot senescence as an initiating event triggering lytic bone disease in breast cancer metastases. Significance: Breast cancer cells remodel the bone microenvironment by promoting premature cellular senescence and SASP in osteocytes, which can be targeted with senolytics to alleviate bone loss induced by metastatic breast cancer. See related commentary by Frieling and Lynch, p. 3917.
The Innate Immune System and TRAIL-BCL-XL Axis Mediate a Sex Bias in Lung Cancer and Confer a Therapeutic Vulnerability in Females
Authors: Lauren May, Bin Hu, Preksha Jerajani, Akash Jagdeesh, Ohud Alhawiti, Lillian Cai, Nina Semenova, Chunqing Guo, Madison Isbell, Xiaoyan Deng, Anthony Faber, Raghavendra Pillappa, Dipankar Bandyopadhyay, Xiang-Yang Wang, Alexander Neuwelt, Jennifer Koblinski, Paula D. Bos, Howard Li, Rebecca Martin, Joseph W. Landry
Journal: Cancer Research (2024)

There is a significant sex-bias in lung cancer with males showing increased mortality compared to females. A better mechanistic understanding of these differences could help identify therapeutic targets to personalize cancer therapies to each sex. After observing a clear sex-bias in humanized mice, with male patient-derived xenograft (PDX) lung tumors being more progressive and deadlier than female PDX lung tumors, we identified mouse tumor models of lung cancer with the same sex-bias. This sex-bias was not observed in models of breast, colon, melanoma, and renal cancers. In vivo, the sex-bias in growth and lethality required intact ovaries, functional innate natural killer (NK) cells and monocytes/macrophages, and the activating receptor NKG2D. Ex vivo cell culture models were sensitized to the anti-cancer effects of NKG2D-mediated NK cell and macrophage killing through the TRAIL-BCL-XL axis when cultured with serum from female mice with intact ovaries. In both flank and orthotopic models, the BCL-XL inhibitor navitoclax (ABT-263) improved tumor growth control in female mice and required NK cells, macrophages, and the TRAIL signaling pathway. This research suggests that navitoclax and TRAIL pathway agonists could be used as a personalized therapy to improve outcomes in women with lung cancer.
Virtual Peer Support for ICU Survivors Is Feasible, and May Improve Outcomes for ICU Survivors: Results from the icuRESOLVE-D (icu Recovery Solutions Co-Designed through SurVivor Engagement – Digital) Pilot Randomised Controlled Trial
Authors: Nina Leggett, Yasmine Ali Abdelhamid, Erin Bicknell, Sarah Booth, Jacki Carmody, Adam M. Deane, KJ Farley, Amalia Karahalios, Mark Merolli, Kimberley J Haines
Journal: American Journal of Respiratory and Critical Care Medicine (2024)
Relationship Between Average Glucose Levels and HbA1c Differs Across Racial Groups: A Substudy of the GRADE Randomized Trial
Authors: David M. Nathan, William H. Herman, Mary E. Larkin, Heidi Krause-Steinrauf, Hiba Abou Assi, Andrew J. Ahmann, Janet Brown-Friday, Daniel S. Hsia, Tasma Harindhanavudhi, Mary Johnson, Valerie L. Arends, Nicole M. Butera, Samuel P. Rosin, John M. Lachin, Naji Younes, B.M. Everett, I. Abdouch, G. Bahtiyar, P. Brantley, F.E. Broyles, G. Canaris, P. Copeland, J.J. Craine, W.L. Fein, A. Gliwa, L. Hope, M.S. Lee, R. Meiners, V. Meiners, H. O’Neal, J.E. Park, A. Sacerdote, E. Sledge, L. Soni, J. Steppel-Reznik, A. Turchin
Journal: Diabetes Care (2024)

To determine whether the relationship between average glucose (AG) levels and hemoglobin A1c (HbA1c) differs across racial/ethnic groups.
SLEEP DISORDERS AND RISK OF ALZHEIMER'S DISEASE: A TWO-WAY ROAD
Authors: Rafael Antônio Vicente Lacerda, Janaína Aparecida Favero Desio, Camila Marciele Kammers, Silvana Henkes, de SaMonique Freitas de Sá, Everton Ferreira de Souza, Driele Martins da Silva, GusmaoCamilla Teixeira Pinheiro Gusmão, Júlio César Claudino Dos Santos
Journal: Ageing Research Reviews (2024)
Selective Enhancer Gain of Function Deregulates MYC Expression in Multiple Myeloma
Authors: Mahshid Rahmat, Kendell Clement, Jean-Baptiste Alberge, Romanos Sklavenitis-Pistofidis, Rohan Kodgule, Charles P. Fulco, Daniel Heilpern-Mallory, Katarina Nilsson, David Dorfman, Jesse M. Engreitz, Gad Getz, Luca Pinello, Russell Ryan, Irene M. Ghobrial
Journal: Cancer Research (2024)

MYC deregulation occurs in the majority of multiple myeloma (MM) cases and is associated with progression and worse prognosis. Enhanced MYC expression occurs in about 70% of MM patients, but it is known to be driven by translocation or amplification events in only ~40% of myelomas. Here, we used CRISPR interference (CRISPRi) to uncover an epigenetic mechanism of MYC regulation whereby increased accessibility of a plasma cell-type specific enhancer leads to increased MYC expression. This native enhancer activity was not associated with enhancer hijacking events but led to specific binding of c-MAF, IRF4, and SPIB transcription factors that activated MYC expression in the absence of known genetic aberrations. In addition, focal amplification was another mechanism of activation of this enhancer in approximately 3.4% of MM patients. Together, these findings define an epigenetic mechanism of MYC deregulation in MM beyond known translocations or amplifications and point to the importance of non-coding regulatory elements and their associated transcription factor networks as drivers of MM progression.
Pulmonary <i>FABP4</i> Is an Inverse Biomarker of Pneumonia in Critically Ill Children and Adults
Authors: Emily C. Lydon, Hoang Van Phan, Eran Mick, Natasha Spottiswoode, Carolyn S Calfee, Peter M Mourani, Charles R. Langelier
Journal: American Journal of Respiratory and Critical Care Medicine (2024)
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes
Authors: Ammar W Bhatti, Rushin Patel, Sourbha S Dani, Sumanth Khadke, Bhargav Makwana, Candace Lessey, Jui Shah, Zaid Al-Husami, Eric H Yang, Paaladinesh Thavendiranathan, Tomas G Neilan, Diego Sadler, Richard K Cheng, Susan F Dent, Jennifer Liu, Teresa Lopez-Fernandez, Joerg Herrmann, Marielle Scherrer-Crosbie, Daniel J Lenihan, Salim S Hayek, Bonnie Ky, Anita Deswal, Ana Barac, Anju Nohria, Sarju Ganatra
Journal: JACC CardioOncology (2024)
Post-hospitalisation COVID-19 cognitive deficits at one year are global and associated with elevated brain injury markers and grey matter volume reduction
Authors: Greta K Wood, Brendan F Sargent, Zain-Ul-Abideen Ahmad, Kukatharmini Tharmaratnam, Cordelia Dunai, Franklyn N Egbe, Naomi H Martin, Bethany Facer, Sophie L Pendered, Henry C Rogers, Christopher Hübel, Daniel J van Wamelen, Richard A I Bethlehem, Valentina Giunchiglia, Peter J Hellyer, William Trender, Gursharan Kalsi, Edward Needham, Ava Easton, Thomas A Jackson, Colm Cunningham, Rachel Upthegrove, Thomas A Pollak, Matthew Hotopf, Tom Solomon, Sarah L Pett, Pamela J Shaw, Nicholas Wood, Neil A Harrison, Karla L Miller, Peter Jezzard, Guy Williams, Eugene P Duff, Steven Williams, Fernando Zelaya, Stephen M Smith, Simon Keller, Matthew Broome, Nathalie Kingston, Masud Husain, Angela Vincent, John Bradley, Patrick Chinnery, David K Menon, John P Aggleton, Timothy R Nicholson, John-Paul Taylor, Anthony S David, Alan Carson, Ed Bullmore, Gerome Breen, Adam Hampshire, Benedict D Michael, Stella-Maria Paddick, E Charles Leek
Journal: Nature Medicine (2024)
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
Authors: F André, N Solovieff, F Su, A Bardia, P Neven, Y S Yap, D Tripathy, Y-S Lu, D Slamon, S Chia, M Joshi, A Chakravartty, A Lteif, T Taran, C L Arteaga
Journal: Annals of Oncology (2024)
A toolbox for surfacing health equity harms and biases in large language models
Authors: Stephen R Pfohl, Heather Cole-Lewis, Rory Sayres, Darlene Neal, Mercy Asiedu, Awa Dieng, Nenad Tomasev, Qazi Mamunur Rashid, Shekoofeh Azizi, Negar Rostamzadeh, Liam G McCoy, Leo Anthony Celi, Yun Liu, Mike Schaekermann, Alanna Walton, Alicia Parrish, Chirag Nagpal, Preeti Singh, Akeiylah Dewitt, Philip Mansfield, Sushant Prakash, Katherine Heller, Alan Karthikesalingam, Christopher Semturs, Joelle Barral, Greg Corrado, Yossi Matias, Jamila Smith-Loud, Ivor Horn, Karan Singhal
Journal: Nature Medicine (2024)
Self-sustaining long-term 3D epithelioid cultures reveal drivers of clonal expansion in esophageal epithelium
Authors: Albert Herms, David Fernandez-Antoran, Maria P Alcolea, Argyro Kalogeropoulou, Ujjwal Banerjee, Gabriel Piedrafita, Emilie Abby, Jose Antonio Valverde-Lopez, Inês S Ferreira, Irene Caseda, Maria T Bejar, Stefan C Dentro, Sara Vidal-Notari, Swee Hoe Ong, Bartomeu Colom, Kasumi Murai, Charlotte King, Krishnaa Mahbubani, Kourosh Saeb-Parsy, Alan R Lowe, Moritz Gerstung, Philip H Jones
Journal: Nature Genetics (2024)
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
Authors: Scott Kopetz, Danielle A Murphy, Jie Pu, Fortunato Ciardiello, Jayesh Desai, Eric Van Cutsem, Harpreet Singh Wasan, Takayuki Yoshino, Hedieh Saffari, Xiaosong Zhang, Phineas Hamilton, Tao Xie, Rona Yaeger, Josep Tabernero
Journal: Nature Medicine (2024)
The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships
Authors: Josepine Fernow, Marie Olliver, William Couet, Sophie Lagrange, Meindert H. Lamers, Ole F. Olesen, Kristina Orrling, Michel Pieren, Derek J. Sloan, Juan José Vaquero, Timothy J. Miles, Anders Karlén
Journal: Nature Reviews Drug Discovery (2024)
A phenome-wide association study of methylated GC-rich repeats identifies a GCC repeat expansion in AFF3 associated with intellectual disability
Authors: Bharati Jadhav, Paras Garg, Joke J F A van Vugt, Kristina Ibanez, Delia Gagliardi, William Lee, Mariya Shadrina, Tom Mokveld, Egor Dolzhenko, Alejandro Martin-Trujillo, Scott J Gies, Gabrielle Altman, Clarissa Rocca, Mafalda Barbosa, Miten Jain, Nayana Lahiri, Katherine Lachlan, Henry Houlden, Benedict Paten, Jan Veldink, Arianna Tucci, Andrew J Sharp
Journal: Nature Genetics (2024)
Federated analysis of autosomal recessive coding variants in 29,745 developmental disorder patients from diverse populations
Authors: V Kartik Chundru, Zhancheng Zhang, Klaudia Walter, Sarah J Lindsay, Petr Danecek, Ruth Y Eberhardt, Eugene J Gardner, Daniel S Malawsky, Emilie M Wigdor, Rebecca Torene, Kyle Retterer, Caroline F Wright, Hildur Ólafsdóttir, Maria J Guillen Sacoto, Akif Ayaz, Ismail Hakki Akbeyaz, Dilşad Türkdoğan, Aaisha Ibrahim Al Balushi, Aida Bertoli-Avella, Peter Bauer, Emmanuelle Szenker-Ravi, Bruno Reversade, Kirsty McWalter, Eamonn Sheridan, Helen V Firth, Matthew E Hurles, Kaitlin E Samocha, Vincent D Ustach, Hilary C Martin
Journal: Nature Genetics (2024)
Characterization of myeloid‐derived suppressor cells in the peripheral blood and bone marrow of patients with chronic idiopathic neutropenia
Authors: Nikoleta Bizymi, Athina Damianaki, Nikoletta Aresti, Anastasios Karasachinidis, Zacharenia Vlata, Matthieu Lavigne, Emmanuel Dialynas, Niki Gounalaki, Irene Stratidaki, Grigorios Tsaknakis, Aristea Batsali, Irene Mavroudi, Maria Velegraki, Ioannis Sperelakis, Charalampos Pontikoglou, Panayotis Verginis, Helen A. Papadaki
Journal: HemaSphere (2024)
Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes
Authors: Thomas G Hill, Rui Gao, Anna Benrick, Lakshmi Kothegala, Nils Rorsman, Cristiano Santos, Samuel Acreman, Linford J Briant, Haiqiang Dou, Nikhil R Gandasi, Claudia Guida, Elizabeth Haythorne, Marsha Wallace, Jakob G Knudsen, Caroline Miranda, Johan Tolö, Anne Clark, Lucy Davison, Joachim Størling, Andrei Tarasov, Frances M Ashcroft, Patrik Rorsman, Quan Zhang
Journal: Nature Metabolism (2024)